OGN Quote, Financials, Valuation and Earnings

Arvinas has a net margin of 5.75% compared to Organon &'s net margin of 43.91%. Organon &'s return on equity of 220.72% beat Arvinas's return on equity of -7.72%.

Organon & has a consensus price target of $13.33, signalling upside risk potential of 38.46%. On the other hand Arvinas has an analysts' consensus of $19.36 which suggests that it could grow by 155.09%. Given that Arvinas has higher upside potential than Organon &, analysts believe Arvinas is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arvinas has a beta of 2.171, suggesting its more volatile than the S&P 500 by 117.131%.

Organon & has a quarterly dividend of $0.02 per share corresponding to a yield of 8.93%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.5B, which are larger than Arvinas quarterly revenues of $188.8M. Organon &'s net income of $87M is higher than Arvinas's net income of $82.9M. Notably, Organon &'s price-to-earnings ratio is 3.34x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.40x versus 1.28x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Fortrea Holdings has a net margin of 5.75% compared to Organon &'s net margin of -86.43%. Organon &'s return on equity of 220.72% beat Fortrea Holdings's return on equity of -58.22%.

Organon & has a consensus price target of $13.33, signalling upside risk potential of 38.46%. On the other hand Fortrea Holdings has an analysts' consensus of $6.66 which suggests that it could grow by 35.9%. Given that Organon & has higher upside potential than Fortrea Holdings, analysts believe Organon & is more attractive than Fortrea Holdings.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortrea Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Organon & has a quarterly dividend of $0.02 per share corresponding to a yield of 8.93%. Fortrea Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Fortrea Holdings pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.5B, which are larger than Fortrea Holdings quarterly revenues of $651.3M. Organon &'s net income of $87M is higher than Fortrea Holdings's net income of -$562.9M. Notably, Organon &'s price-to-earnings ratio is 3.34x while Fortrea Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.40x versus 0.16x for Fortrea Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 5.75% compared to Organon &'s net margin of 21.68%. Organon &'s return on equity of 220.72% beat Eli Lilly and's return on equity of 78.25%.

Organon & has a consensus price target of $13.33, signalling upside risk potential of 38.46%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Organon & has higher upside potential than Eli Lilly and, analysts believe Organon & is more attractive than Eli Lilly and.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Organon & has a quarterly dividend of $0.02 per share corresponding to a yield of 8.93%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Organon & pays 34.38% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.5B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Organon &'s net income of $87M is lower than Eli Lilly and's net income of $2.8B. Notably, Organon &'s price-to-earnings ratio is 3.34x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.40x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 5.75% compared to Organon &'s net margin of -907.48%. Organon &'s return on equity of 220.72% beat Moderna's return on equity of -29.23%.

Organon & has a consensus price target of $13.33, signalling upside risk potential of 38.46%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Organon &, analysts believe Moderna is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Organon & has a quarterly dividend of $0.02 per share corresponding to a yield of 8.93%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.5B, which are larger than Moderna quarterly revenues of $107M. Organon &'s net income of $87M is higher than Moderna's net income of -$971M. Notably, Organon &'s price-to-earnings ratio is 3.34x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.40x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.